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Purpose: Dasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The 
recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 
70 mg twice daily to 100 mg once daily following a Phase III dose-optimization study. To better 
understand the superior benefit–risk profile of dasatinib 100 mg once daily, exposure–response 
was characterized for efficacy (major cytogenetic response) and safety (pleural effusion).
Patients and methods: Dasatinib exposure in patients with chronic myeloid leukemia in 
chronic phase was determined by population pharmacokinetic analysis of data from seven 
dasatinib clinical studies (N = 981), including the Phase III dose-optimization study (n = 567). 
Data from the Phase III study were then used to characterize exposure–response relationships 
for the four dasatinib treatment regimens investigated (100 mg once daily, 50 mg twice daily, 
140 mg once daily, and 70 mg twice daily).
Results: Major cytogenetic response was significantly (P , 0.01) associated with weighted 
average steady-state dasatinib plasma concentrations, and pleural effusion was significantly 
associated with trough concentration. Major cytogenetic response was also significantly asso-
ciated with maintenance of uninterrupted dosing. The 100 mg once daily arm had the lowest 
steady-state trough concentration of the four dose arms investigated in the Phase III study, and 
although this arm also had the lowest weighted average steady-state dasatinib plasma concen-
tration, it had the highest dose maintenance.
Conclusion: Dasatinib dose optimization to 100 mg once daily from 70 mg twice daily sig-
nificantly minimizes adverse events while maintaining efficacy by exploiting differences in the 
measures of exposure associated with efficacy and safety.
Keywords: chronic myeloid leukemia, pharmacokinetics, major cytogenetic response, pleural 
effusion
Introduction
In 2010, chronic myeloid leukemia (CML) accounted for 11% of all adult leukemias 
diagnosed in the United States.1,2 CML is characterized by the fusion of a portion of 
the ABL1 oncogene on chromosome 9 with the breakpoint cluster region gene (BCR) 
on chromosome 22 to form the BCR-ABL1 gene.1 This oncogene encodes a consti-
tutively active tyrosine kinase protein (BCR-ABL1) that can activate multiple signal 
transduction pathways affecting hematopoietic cell growth and survival.3 BCR-ABL1 
tyrosine kinase inhibitors (TKIs) (imatinib, dasatinib, and nilotinib) are currently the 
mainstays of CML treatment.4
Dasatinib is a prototypic short half-life TKI (plasma half-life approximately 4 to 
6 hours)5 that inhibits BCR-ABL1 with a potency 325-fold that of imatinib in vitro. 
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It is also active against several imatinib-resistant BCR-
ABL1 mutants.6 Dasatinib was initially approved for the 
treatment of adults with Philadelphia chromosome–positive 
(Ph+) CML in chronic, accelerated, or myeloid/lymphoid 
blast phase (CML-CP, -AP, or -BP, respectively) with resis-
tance or intolerance to prior therapy, including imatinib, 
or Ph+ acute lymphoblastic leukemia (ALL) with resistance 
or intolerance to prior therapy.7 It has since been approved for 
the treatment of newly diagnosed adults with Ph+ CML-CP. 
Dose and schedule were initially explored in a Phase I dose-
escalation study in which 84 patients with CML or Ph+ ALL 
that was resistant or intolerant to imatinib received dasatinib 
(15–240 mg/day) once daily or twice daily.8 In this study, 
the 70 mg twice daily dose showed the most notable rates of 
major cytogenetic response (MCyR) in both CML-CP (four 
of six patients) and advanced-phase CML (CML-AP or -BP) 
(ten of 17 patients).8 Based in large part upon the plasma half-
life observed in this study, dasatinib 70 mg twice daily was 
further assessed in five Phase II studies in patients across all 
phases of CML and Ph+ ALL (the Src/Abl Tyrosine kinase 
inhibition Activity: Research Trials [START]).9–13 These 
studies served as the basis for approval of the 70 mg twice 
daily dose in the United States and Europe for Ph+ CML (CP, 
AP, and BP) and Ph+ ALL in patients intolerant or resistant 
to imatinib.14,15
Retrospective analysis data from the Phase I and Phase II 
studies in patients with CML suggested that pleural effusion, 
a key adverse event (AE) associated with dasatinib therapy, 
is less frequent with once daily dosing compared with twice 
daily dosing and at doses of #100 mg/day compared with 
doses of #140 mg/day.16 Additionally, in two of the Phase II 
studies of dasatinib 70 mg twice daily in patients with CML-
CP, the mean total daily dose following dose reductions and 
interruptions was approximately 100 mg.11,12 Based on these 
data, the dasatinib dose and schedule were prospectively 
reassessed in an open-label Phase III study of patients with 
CML-CP17,18 in which patients were equally randomized to 
four dasatinib treatment regimens (100 mg once daily, 50 mg 
twice daily, 140 mg once daily, and 70 mg twice daily). 
Similar MCyR rates were observed with dasatinib 100 mg 
once daily (n = 167) and 70 mg twice daily (n = 168) (59% 
and 55%, respectively), whereas dasatinib 100 mg once daily 
was associated with significantly lower frequencies of grade 
3–4 AEs (30% versus 48%) (P = 0.001), grade 3–4 throm-
bocytopenia (22% versus 37%) (P = 0.004), and any-grade 
pleural effusion (7% versus 16%) (P = 0.024) compared with 
dasatinib 70 mg twice daily.17 Furthermore, fewer patients 
required dose interruptions and reductions due to toxicity in 
the 100 mg once daily arm versus the 70 mg twice daily arm.17 
These data led to a new approved starting dose of 100 mg 
once daily for patients with CML-CP.19
The exposure–response (E–R) relationship was charac-
terized with respect to efficacy (MCyR) and safety (pleural 
effusion) to better understand and quantify the factors under-
lying the superior benefit–risk balance of dasatinib 100 mg 
once daily compared with dasatinib 70 mg twice daily 
in patients with Ph+ CML-CP.  A previously developed popula-
tion pharmacokinetic (PPK) model20 was updated with data 
from the Phase III dose-optimization study and applied to 
determine summary measures of individual dasatinib expo-
sure (both steady-state and time-dependent peak, trough, 
and time-averaged plasma dasatinib concentrations). These 
exposure measures were used to characterize dasatinib E–R 
relationships for efficacy (attainment of MCyR) and safety 
(pleural effusion incidence). MCyR was selected for the 
exposure–efficacy response analysis because it was the primary 
endpoint in the Phase III dose-optimization study.17 Pleural 
effusion was selected for the exposure–safety response analysis 
because it is the most common fluid retention event reported in 
patients with CML treated with second-line dasatinib.21
Methods
Data
The pharmacokinetics of dasatinib in subjects with CML-
CP was described by a PPK model, developed using data 
from seven open-label clinical studies in patients with CML 
(one Phase I dose-escalation study of dasatinib 15–180 mg 
once daily and 25–120 mg twice daily; five Phase II studies 
of dasatinib 70 mg twice daily [START-A, -B, -C, -L, and 
-R]; and the Phase III dose-optimization study).8–13,17 This 
model was applied to determine the dasatinib exposure of 
subjects in the Phase III dose-optimization study from the 
available, sparse dasatinib concentration measurements in 
these  subjects. The dasatinib E–R for MCyR and pleural 
effusion was characterized using data from subjects in the 
Phase III dose-optimization study for whom dasatinib expo-
sure could be determined. The studies included in the PPK 
and E–R analyses are summarized in Table S1. All studies 
were approved by the relevant Institutional Review Boards 
and Independent Ethics Committees of each participating 
institution and were conducted in accordance with the ethical 
principles of the Declaration of Helsinki.
The PPK analysis dataset included a total of 6457 dasatinib 
plasma concentration values from 981 patients with Ph+ CML 
(CP, AP, and BP) or Ph+ ALL that was resistant or intolerant 
to prior therapy from the seven open-label clinical studies. 
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Baseline demographic and laboratory measurements were 
recorded and included in the analysis dataset. A summary 
of patient demographics and laboratory values included in 
the PPK model are shown in Table S2.
Efficacy and safety E–R analyses were performed on 
data from 567 (86%) of 662 patients with CML-CP treated 
with dasatinib in the Phase III dose-optimization study for 
whom dasatinib exposure could be determined. The median 
age was 55 years (range 18–84), and 47% (266/567) of 
patients were male. In total, 34% of patients (191/567) had 
a history of cardiac disease. Most patients (74%, 417/567) 
were imatinib-resistant, and the others (26%, 150/567) were 
imatinib-intolerant.
The primary endpoint for efficacy in the Phase III study 
was achievement of MCyR after a minimum follow-up of 
6 months. Patients were considered to have achieved MCyR 
if they had #35% Ph+ metaphases in bone marrow.17 Safety 
evaluations included pleural effusion incidence and time to 
first reported pleural effusion (any grade).17,22 Chest X-rays 
were performed at baseline, after 6 months of treatment, and 
as required for detection or monitoring of pleural effusion.
Analyses
PPK model
The PPK model was developed by updating a previously 
developed model20 with dasatinib plasma concentration 
data collected in the Phase III dose-optimization study. 
Covariate effects (age, gender, race, body weight, body mass 
index, baseline hepatic and renal laboratory parameters, 
 hemoglobin, and white blood cell count) on PK parameters 
(clearance and volume of distribution) were evaluated by the 
likelihood ratio test. Only covariate effects that were both 
statistically significant (P , 0.001) and clinically relevant 
(defined on the basis of covariate inclusion that resulted in 
more than a ±20% parameter change) were retained in the 
final PPK model. Although no formal adjustment was made 
for multiplicity, the significance level of 0.1% was selected 
in consideration of the multiple parameter–covariate relation-
ships assessed. The model assumed random inter individual 
variability (IIV) with a log-normal distribution on all struc-
tural model parameters. In addition, an interoccasion vari-
ability component (IOV) was used to describe the random 
variability in relative bioavailability within an individual 
and between dosing occasions. The difference between 
observed values and the corresponding model-predicted 
values was described by a log-normal residual error model. 
A model evaluation was conducted using visual predictive 
performance checks on the Phase III study data. The observed 
dasatinib plasma concentration–time data and corresponding 
fifth, 50th, and 95th percentiles of the model-based predic-
tions were plotted as a graphical assessment.
The PPK model was applied to determine summary 
measures of dasatinib steady-state exposure for the nomi-
nal dose (steady-state peak, trough, and time-averaged 
plasma dasatinib concentrations [C
max
ss, C
min
ss, and C
avg
ss, 
respectively]) from the maximum a posteriori estimates of 
individual PK parameters. C
avg
ss was calculated as the ratio 
of the steady-state area under the curve to the dosing interval 
(24 hours for once daily and 12 hours for twice daily). The 
model also was applied to obtain the time-dependent peak, 
trough, and time-averaged plasma dasatinib concentrations 
(C
max
, C
min
, and C
avg
, respectively) given the actual dosing 
history (including dose interruptions and modifications). 
The model was developed using NONMEM® (version VI, 
level 1.1; Icon plc, Dublin, Republic of Ireland). Diagnostic 
graphics, exploratory analyses, and postprocessing of NON-
MEM® output were performed using S-PLUS (version 7.0.0 
for Linux; TIBCO Software Inc, Palo Alto, CA, USA).
E–R for efficacy: MCyR
The relationship between dasatinib exposure and the prob-
ability of achieving MCyR was described by a logistic 
regression model. The marginal effect of dasatinib exposure 
on MCyR was first characterized in a base model, followed 
by examination of effects from patient covariates in a full 
model. The following patient covariates were examined: 
age, gender, imatinib failure status (resistant or intolerant), 
and duration of dose maintenance (uninterrupted duration as 
percentage of total treatment duration). The final model was 
developed by backward elimination of covariate effects from 
the full model and contained effects from both exposure 
measures and covariates that had statistically significant 
effects (P , 0.01). Although no formal adjustment was made 
for multiplicity the significance level of 1% was selected in 
consideration of the multiple covariates assessed. The expo-
sure measures (C
max
ss, C
min
ss, and C
avg
ss) for each patient 
were adjusted to account for dose modification by multiplying 
these values by the weighted average total daily dose taken 
by the patient (expressed as a percentage of the nominal 
dose) to obtain the corresponding weighted average expo-
sures (wC
max
ss, wC
min
ss, and wC
avg
ss). The weighted average 
total daily dose of each patient was calculated as the daily 
dose averaged over the duration of uninterrupted treatment 
(treatment duration excluding dose interruptions) up to time 
of MCyR or end of treatment, whichever occurred earlier. 
The potential effect of dose interruption was assessed with 
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respect to dose maintenance (D
m
) (expressed as the percent-
age of uninterrupted treatment duration). The final model 
was evaluated by assessing the agreement between the 
observed proportion of MCyR and the 90% model predic-
tion intervals.
E–R for safety: pleural effusion
The relationship between dasatinib exposure and the time to 
first occurrence of grade $ 1 pleural effusion was described 
by a Cox proportional hazards model. The marginal effect 
of dasatinib exposure on the occurrence of pleural effusion 
was first characterized in a base model, followed by the 
examination of effects from patient covariates (age, gender, 
race, and history of cardiac disease) in a full model. The final 
model was developed by backward elimination of covariate 
effects from the full model and contained both exposure 
measures and covariates with statistically significant effects 
(P , 0.01). Although no formal adjustment was made for 
multiplicity, the significance level of 1% was selected in 
consideration of the multiple covariates assessed. The mea-
sures of exposure assessed were C
max
, C
min
, and C
avg
, and the 
model was evaluated by comparing the predicted cumula-
tive probability of pleural effusion with that determined by 
Kaplan–Meier analysis.
Results
PPK analysis
The dasatinib concentration–time data were well-described 
by a linear two-compartment PPK model. The model was 
parameterized in terms of plasma and intercompartmental 
apparent clearances, apparent volumes of distribution in the 
central and peripheral compartments, and the absorption rate 
constant (Table 1). The mean terminal half-life was estimated 
to be 2.93 hours. The variability in relative bioavailability (IIV 
of 34.6% and IOV of 37.4%) accounted for a larger portion of 
overall variability in dasatinib exposure than did the variability 
in the apparent plasma clearance (28.8%). None of the cova-
riates examined during model development had statistically 
significant effects (P , 0.001) or clinically relevant effects 
(.±20% effect) on the PK  parameters. Therefore, the final 
PPK model contained no covariate effects.  Evaluation of the 
diagnostic plots, such as the model predictions  versus observa-
tions, residuals versus model  predictions, and residuals versus 
time, showed that the model described the observed data well, 
and assumptions about random variability (ie, IIV, IOV, and 
residual error) were reasonably satisfied (data not shown).
Figure 1 shows the observed and model-predicted 
median (90% prediction intervals) of dasatinib plasma 
 concentration versus time for the four arms of the Phase III 
Table 1 Final PPK model parameter estimates
Parameter  
(units)
Estimatea Standard error  
(RSE%)
95% CIb
Fixed effects
 (CL/F)TV (L/h) 296 6.42 (2) 283–309
 (Vc/F)TV (L) 1230 63.7 (5) 1110–1350
 (Q/F)TV (L/h) 119 6.05 (5) 107–131
 (Vp/F)TV (L) 1030 38.9 (4) 954–1110
 KATV (1/h) 2.1 0.15 (7.3) 1.8–2.4
Random effects
 ω2CL 0.083 (0.29) 0.016 (19.6) 0.051–0.114
 ω2Vc 0.730 (0.85) 0.073 (10.0) 0.587–0.873
 ω2KA (fixed) 1.0 (1.0) – –
 ω2FR 0.120 (0.35) 0.020 (16.2) 0.082–0.158
 ω2FR,IOV 0.140 (0.37) 0.008 (5.6) 0.125–0.155
 ω2CL,Vc 0.241 (0.98) 0.031 (12.8) 0.181–0.301
Residual error
 σL 0.464 0.002 (0.537) 0.459–0.469
Notes: aEstimate values in parentheses are standard deviations for estimated 
variances (first five entries under random effects) and correlation for estimated 
covariance (last entry under random effects); bbootstrap confidence intervals (327 
successful out of a total of 500).
Abbreviations: CI, confidence interval; (CL/F)TV, apparent clearance; KATV, 
absorption rate constant; PPK, population pharmacokinetics; (Q/F)TV, apparent 
intercompartmental clearance; RSE%, relative standard error as a percentage of 
the estimate; (Vc/F)TV, apparent volume of central compartment; (Vp/F)TV, apparent 
volume of peripheral compartment; σL, standard deviation of log-additive residual 
error; ω2CL, variance of interindividual variability for apparent clearance; ω2CL,Vc, 
covariance for apparent clearance and apparent volume of central compartment; 
ω2FR, variance of interindividual variability for relative bioavailability; ω2FR,IOV, variance 
of interoccasion variability for relative bioavailability; ω2KA, variance of interindividual 
variability for absorption rate constant; ω2Vc, variance of interindividual variability 
for apparent volume of central compartment.
dose-optimization study. Overall, the predicted concentra-
tions corresponded well to the observed profiles from the 
study. The percentage of observations outside the 90% predic-
tion intervals was generally less than 10%, suggesting that 
the model had no systematic bias with respect to the dose or 
frequency of dasatinib administration.
The PPK-model–predicted exposures for the 567 patients 
in the Phase III study show that the C
min
ss was lowest for the 
100 mg once daily regimen and that the C
avg
ss was similar for 
the 100 mg once daily and 50 mg twice daily regimens and 
for the 140 mg once daily and 70 mg twice daily regimens 
(Table 2). These data showed that for a given daily dose, C
min
ss 
tends to be lower for the once daily schedule whereas C
max
ss 
tends to be higher. The weighted average exposure measures 
showed similar trends. These summary measures and their 
time-dependent correlates were subsequently applied in the 
dasatinib exposure–efficacy and exposure–safety analyses 
after adjustments for dose modifications that were appropriate 
for each analysis, as described in the Methods section.
E–R for efficacy: MCyR
During treatment, 63% (358/567) of patients in the Phase III 
dose-optimization study achieved MCyR.  Similar MCyR 
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Figure 1 Observed and predicted median concentrations versus time from previous dose for dasatinib in the Phase III study.17,18
Note: Predicted median concentrations have a 90% prediction interval.
Table 2 Geometric mean (CV%) of weighted average daily dose, dose maintenance, and steady-state dasatinib exposures of patients 
in the Phase III study
100 mg once daily 
n = 146
50 mg twice daily 
n = 148
140 mg once daily 
n = 141
70 mg twice daily 
n = 132
wTDD 
(% nominal)
94.1 (16) 92.0 (17) 87.9 (16) 85.7 (20)
Dm (%) 87.8 (19) 84.8 (20) 84.4 (20) 85.1 (17)
Cminss (ng/mL) 2.61 (26) 5.00 (24) 3.72 (28) 6.71 (24)
C
max
ss (ng/mL) 54.6 (56) 32.8 (48) 79.7 (55) 47.8 (46)
Cavgss (ng/mL) 13.5 (35) 14.3 (31) 19.7 (32) 20.0 (31)
wCminss (ng/mL) 2.46 (28) 4.59 (29) 3.32 (31) 5.75 (31)
wC
max
ss (ng/mL) 51.4 (58) 30.2 (49) 71.2 (58) 40.9 (52)
wCavgss (ng/mL) 12.7 (36) 13.1 (33) 17.5 (34) 17.1 (37)
Abbreviations: Cavgss, steady-state time-averaged plasma dasatinib concentration; Cmaxss, steady-state peak plasma dasatinib concentration; Cminss, steady-state trough 
plasma dasatinib concentration; Dm, percentage dose maintenance duration; wCavgss, weighted average steady-state plasma dasatinib concentration; wCmaxss, weighted 
average steady-state peak plasma dasatinib concentration; wCminss, weighted average steady-state trough plasma dasatinib concentration; wTDD, weighted average 
total daily dose.
rates were achieved across the four regimens: 64% (100 mg 
once daily), 57% (50 mg twice daily), 68% (140 mg once 
daily), and 64% (70 mg twice daily). Of patients included 
in the analysis dataset, 61% (217/358) of the responders 
had dose modifications (including dose escalations or 
 interruptions/reductions due to hematologic or nonhema-
tologic toxicity) before achieving MCyR. The predictor 
variables investigated in the analysis (D
m
, wC
max
ss, wC
min
ss, 
and wC
avg
ss) are summarized in Table 2. Dasatinib 100 mg 
once daily and 70 mg twice daily had mean reductions of 
6% and 14% from their nominal daily dose, respectively.
wC
avg
ss was identified as the most significant exposure 
predictor for achieving MCyR in the base model. The mag-
nitude of the effect of predictor variables assessed in the full 
model is shown in Figure S1. The effect of gender was not 
statistically significant and, therefore, not included in the 
final model. The final logistic regression model (Table 3) 
indicated that the probability of achieving MCyR in CML-CP 
patients was significantly greater (P , 0.01) with increas-
ing wC
avg
ss (odds increased 2.11-fold for every doubling of 
the wC
avg
ss), increasing D
m
 (odds increased 1.60-fold for 
every 10% increase of the D
m
), and decreasing age (odds 
decreased 22% for every decade increase in life). Patients 
with imatinib-resistant disease were less likely to respond 
compared with patients with imatinib-intolerant disease 
(odds ratio = 0.52). Given the definition, D
m
 was considered 
an independent predictor of exposure (correlation coefficient 
between wC
avg
ss and D
m
 = −0.1).
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Table 3 Parameter estimates for dasatinib exposure–efficacy (MCyR) and exposure–safety (pleural effusion) relations
Predictora Odds ratio  
coefficientb
95% CI P-value Odds ratio (5th and 95th  
percentiles: median)
Logistic regression model for dasatinib exposure–efficacy (MCyR) relation
Log2(wCavgss) 2.11 1.52–2.91 ,0.001 0.43, 1.83
Dm/10 1.60 1.41–1.81 ,0.001 0.24, 2.51
Age/10 0.78 0.68–0.90 0.001 2.00, 0.62
Imatinib status  
(resistant versus intolerant)
0.52 0.40–0.65 ,0.001 –
Predictor Hazard ratio  
coefficientc
95% CI P-value Hazard ratio (5th and 95th 
percentiles: median)
Cox proportional hazard model for dasatinib exposure–safety (pleural effusion) relation
Cmin 1.22 1.12–1.33 ,0.01 0.63, 2.38
Age/10 2.02 1.69–2.43 ,0.01 0.13, 3.09
Notes: aLog2(wCavgss) increases by one unit for every doubling of wCavgss; Dm/10 increases by one unit for every 10% increase of Dm; Age/10 increases by one unit for every 
increase of 10 years in age; bincrease in odds for every unit increase in the continuous predictor variable, or odds relative to the reference value of the categorical predictor 
variable; cincrease in hazard for every unit increase in the continuous predictor variable. 
Abbreviations: CI, confidence interval; Cmin, trough plasma dasatinib concentration; MCyR, major cytogenetic response; Dm, percentage dose maintenance duration; wCavgss, 
weighted average steady-state plasma dasatinib concentration.
Figure 2 shows the model-predicted probability (95% con-
fidence interval [CI]) of MCyR and an evaluation of the model, 
comparing the observed proportion of MCyR and model-pre-
dicted median proportion of MCyR (90% prediction interval) 
versus the three continuous predictors (wC
avg
ss, D
m
, and age). 
Each panel shows that patients with imatinib-intolerant disease 
had higher response probability. The median predictions fol-
lowed the trend of the relationships, and most of the observed 
response proportions were covered by the 90% intervals of the 
model predictions. The predicted median response rates (with 
90% prediction intervals) for patients treated with dasatinib 
100 mg once daily, 50 mg twice daily, 140 mg once daily, and 
70 mg twice daily were 53% (27%–73%), 20% (7.7%–40%), 
60% (47%–80%), and 47% (27%–67%), respectively. This 
evaluation indicates that, in general, the model described the 
relationship between MCyR rate and each predictor reasonably 
well, although response rate in the 50 mg twice daily group 
was underpredicted by the model.
E–R for safety: pleural effusion
Of the 567 patients included in the E–R analysis of the 
Phase III dose-optimization study, 94 had pleural effusions. 
Pleural effusion rates were 11.0% (100 mg once daily), 
16.2% (50 mg twice daily), 17.7% (140 mg once daily), 
and 22.0% (70 mg twice daily). The C
min
 was identified as 
the most significant predictor of pleural effusion in the base 
model. The magnitudes of covariate effects on the hazard of 
pleural effusion assessed in the full model are shown in Figure 
S2. The effects of cardiac disease history, race (Caucasian/
non-Caucasian), and gender were not significant and were 
removed from the final model. The final model identified 
age (hazard increased 2.02-fold for every decade increase 
in life) and C
min
 (hazard increased 1.22-fold for every 1 ng/
mL increase in C
min
) as statistically significant risk factors for 
pleural effusion (P , 0.01) (Table 3). There was no statisti-
cally significant (P , 0.01) interaction between the C
min
 and 
age, suggesting that age-related variation in C
min
 effect was 
not responsible for age-related variation in response.
Figure 3 illustrates the evaluation of the final model with 
respect to C
min
 and age (.55 years; #55 years) by the four 
dasatinib regimens in the Phase III study. There was  generally 
good agreement between the model-predicted cumulative 
probability of pleural effusion and the  corresponding  pleural 
effusion probability estimates based on Kaplan–Meier 
analysis (the latter lying within the 90% model prediction 
interval), except for a slight overprediction in the 100 mg 
once daily and .55 years age group and a slight underpredic-
tion in the 140 mg once daily and #55 years age group. As 
this discrepancy was not consistent across subgroups, it is 
unlikely to be due to model misspecification. The underpre-
diction noted in the lower age group is most likely a random 
effect, whereas the deviation in the higher age group may be 
due to a weak interaction between age and C
min
. However, 
 adding the interaction term into the final model did not pro-
duce statistical significance.
Discussion
Optimizing therapeutic strategies for BCR-ABL1 inhibi-
tors is an important area of investigation in CML.17,23–25 
Given current recommendations for administering BCR-
ABL1 inhibitor therapy indefinitely to patients who are 
responding to and tolerating these agents,4,26 efforts should 
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be directed toward identifying potentially modifiable risk 
factors associated with the optimization of response and 
tolerability. The original dasatinib 70 mg twice daily regimen 
was selected based on the increased probability of achiev-
ing more continuous BCR-ABL1 inhibition and observed 
 clinical responses in Phase I studies. Despite the short half-
life of dasatinib, responses were nonetheless observed when 
the drug was administered once daily. We used data from the 
Phase III dasatinib dose-optimization study to characterize 
the E–R relationships for efficacy (MCyR) and safety  (pleural 
 effusion) in patients with CML-CP. Our results suggest that 
it was possible to optimize dasatinib dosage because efficacy 
and safety were associated with different measures of expo-
sures: achieving MCyR was most closely related to wC
avg
ss, 
whereas pleural effusion risk was related to C
min
. Chang-
ing the dosing interval from twice daily to once daily and 
reducing the daily dose from 140 mg to 100 mg reduced the 
C
min
 and thereby reduced the probability of pleural effusion. 
Although reduced daily dosing resulted in a nominally lower 
C
avg
ss, the effect of the reduced exposure on efficacy was 
ameliorated by fewer dose modifications and interruptions. 
These results are consistent with the finding that dasatinib 
100 mg once daily was associated with similar efficacy and 
decreased toxicity when compared with the 70 mg twice 
daily regimen.18
The dasatinib concentration–time data for patients 
enrolled in the Phase III dose-optimization study were well-
described by a linear two-compartment PPK model with 
first-order absorption and were consistent with the dasatinib 
PK from earlier studies. The estimated PK parameters, shown 
to be time-invariant, agreed reasonably well with previously 
reported estimates from noncompartmental analyses.20 The 
variability in dasatinib exposure was found to be mainly 
due to IIV and IOV in bioavailability. In contrast, none of 
the examined patient covariates appeared to have a clini-
cally relevant effect on dasatinib pharmacokinetics. These 
findings support the recommendation that dasatinib can be 
administered without dose adjustment for body weight, age, 
gender, or race.21 Dasatinib exposure appears to be dependent 
on dosing regimen, as demonstrated by applying the PPK 
model to the four arms of the Phase III study. Such differ-
entiation in dasatinib exposures provided an opportunity to 
characterize the E–R relationships.
The E–R efficacy analysis results were consistent with 
previous findings that transient exposure to dasatinib is 
equivalent to continuous exposure in vitro and that dos-
ing regimens with once daily dasatinib are as effective in 
achieving rapid and durable clinical responses as twice daily 
treatment.18,27 The most significant predictor of MCyR was 
wC
avg
ss. Because dasatinib pharmacokinetics are linear, 
patients treated with once daily and twice daily schedules 
receiving identical total daily doses should have the same 
probability of achieving MCyR. This expectation was 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
91
Dasatinib exposure–response analysis
Clinical Pharmacology: Advances and Applications 2013:5
P
ro
b
ab
ili
ty
 o
f 
p
le
u
ra
l e
ff
u
si
o
n
Time (days)
100 300 500
1.0
0.8
0.6
0
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
0 100 300 500
0 100 300 500 0 100 300 500
Age: >55 years 
100 mg once daily 50 mg twice daily 70 mg twice daily140 mg once daily
Age: ≤55 years 
100 mg once daily 50 mg twice daily 70 mg twice daily140 mg once daily
Kaplan–Meier estimates
Cox proportional-hazard predictions
(90% prediction interval)
Figure 3 Model-predicted (90% prediction intervals) and Kaplan–Meier estimated time to pleural effusion by age and dasatinib treatment groups.
 consistent with the observed MCyR rates in the Phase III 
study (63% [95% CI, 55.7%–70.8%] with 100 mg once 
daily, 61% [95% CI, 53.5%–68.7%] with 70 mg twice daily, 
63% [95% CI, 55.1%–70.2%] with 140 mg once daily, and 
61% [95% CI, 53.5%–68.7%] with 50 mg twice daily).18 
The analysis also identified D
m
 as a significant predictor 
of MCyR, independent of dose modification. Although the 
predicted transient nature of BCR-ABL1 inhibition with a 
once daily dosing interval does not negatively affect effi-
cacy,17 dose interruptions are expected to have an adverse 
impact, based on our analysis. Patients treated with dasatinib 
100 mg once daily had fewer AEs and dose reductions from 
the nominal daily dose than those treated with 70 mg twice 
daily (6% versus 14%, respectively), as well as fewer dose 
interruptions (12% versus 15%). Therefore, maintaining 
steady dosing may be preferable to higher daily dosing that 
could lead to dose modifications and interruptions. Analyses 
for imatinib also revealed that adherence is a critical factor 
in achieving responses in patients with CML28,29 and that 
low adherence was likely associated with increased imatinib 
dose and AEs, although it must be noted that in contrast to 
dasatinib, imatinib has a prolonged terminal half-life. It is 
reasonable to believe that any causes of suboptimal adher-
ence, eg, a complex route of administration and drug–food or 
drug–drug interactions, could negatively impact exposure 
and hence disease response in real-world settings.
As shown by the data in the Phase III dasatinib study, 
imatinib-intolerant patients are more likely to achieve MCyR 
than those with imatinib-resistant disease.17 Our analysis also 
suggests that younger patients are more likely to achieve a 
MCyR than older patients (odds decreased 22% for every 
decade increase in life). Gender had no significant associa-
tion with response in our analysis. The associations of age 
and gender with response have been studied in patients with 
CML receiving second-line imatinib, with inconsistent 
results.30,31 In one study, age was a significant predictor of 
hematologic and cytogenetic response; however, in another, 
neither age nor gender were independent predictive factors 
for MCyR.30,31
Exposure–safety response analyses performed here iden-
tified C
min
 as having the strongest association with pleural 
effusion occurrence. In the Phase III study, the lowest C
min
ss 
was achieved with the 100 mg once daily schedule, which 
had the best benefit–risk balance of the four treatment regi-
mens.17 An ongoing Phase II study (OPTIM) is prospectively 
evaluating the optimization of residual dasatinib plasma 
levels in patients newly diagnosed with CML-CP.32 In the 
OPTIM study, patients began therapy with dasatinib 100 mg 
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once daily, and the C
max
 and C
min
 were determined after 7 to 
10 days. Patients with C
min
 ,3 nM continued on 100 mg, and 
those with C
min
 .3 nM were randomly assigned to continue 
on 100 mg or to have their dose reduced in 20 mg incre-
ments until the C
min
 (monitored with C
max
 in 15-day intervals) 
decreased to ,3 nM. After C
min
 ,3 nM was achieved, the 
C
min
 and C
max
 were measured every 3 months. After a median 
follow-up of 7.2 months, the C
max
 was found to be associated 
with response, and the C
min
 was associated with fluid retention 
or pleural effusion.32
In addition to the C
min
, age was found to be a significant 
risk factor for pleural effusion. The effect of age is not 
confounded with exposure, as the PPK analysis showed that 
exposure to dasatinib did not depend upon age.  Furthermore, 
the Phase III study was well balanced for age across all 
arms (range of medians, 54–56 years).17 Considering the 
influence of age on pleural effusion risk and the decreased 
 probability of efficacy, the therapeutic window for older 
patients (.55 years of age) with CML-CP may be narrower 
relative to younger patients, and these patients may need more 
 intensive monitoring. Cardiac disease history has previously 
been identified as a risk factor for pleural effusion.16  However, 
in this analysis, cardiac disease history was correlated with 
age (R = 0.4), and the effect of cardiac disease history was 
not significant after accounting for the effect of age.
Patients receiving proton pump inhibitors (PPIs) or his-
tamine-2 receptor antagonists were not excluded from this 
PPK model, although these compounds are likely to reduce 
dasatinib exposure.21,33 For 399 patients with comedication 
data available, the PPK model estimated the ratio of median 
exposure between patients who did and did not receive PPIs 
or histamine-2 receptor antagonists to be 0.95 for dasatinib 
C
min
ss, 0.76 for dasatinib C
max
ss, and 0.85 for dasatinib C
avg
ss. 
This contrasts with results from a drug–drug interaction study 
in healthy volunteers, in which prior administration of a PPI 
reduced dasatinib exposure by approximately 60%.21 The 
more modest effect of PPIs estimated in the current analysis 
may be due to confounding factors, including polypharmacy 
and unknown comedication histories and dosing times.
In general, our data show that opportunities for dose regi-
men optimization exist when the exposure measure most rele-
vant for efficacy is different from that most relevant for safety. 
Whether this approach may be applied to other BCR-ABL1 
TKIs remains controversial. For example,  Larson et al have 
shown the correlation of imatinib C
min
 with both response and 
the occurrence of specific AEs, including fluid retention.34 
Two more analyses also found an association of imatinib C
min
 
with clinical response.35,36 Yet, data from two other imatinib 
studies found no correlation between response and C
min
; 
instead, adherence to the standard imatinib dose was critical 
to achieve response.37,38 All these analyses examined C
min
 as 
the only exposure measure, whereas our analysis examined 
the model-derived C
max
ss, C
min
ss, and C
avg
ss and selected 
the most statistically significant predictor. Our analysis also 
accounted for dose modification. Because of the inconsis-
tencies among these analyses, further research is needed to 
better understand the E–R relationship of BCR-ABL1 TKIs 
as a class. It is possible that the efficacy of those agents with 
prolonged half-lives may correlate better with steady-state 
concentrations. It also remains to be determined whether the 
correlations observed in our analysis are applicable to other 
TKIs with short half-lives.
In conclusion, our analysis shows that dasatinib effi-
cacy and safety were associated with different measures of 
exposure, wC
avg
ss and C
min
. PPK analyses of the dasatinib 
Phase III dose-optimization study confirm that the 100 mg 
once daily schedule was associated with the lowest C
min
ss 
value of the studied schedules, corresponding with improved 
safety compared with dasatinib 70 mg twice daily.18 Our 
analyses highlight opportunities for optimizing BCR-ABL1 
TKI dosing regimens and provide insight into the factors 
that should be considered when selecting an appropriate 
regimen. By quantifying dasatinib E–R relationships, the 
presented analyses establish a link between dosage regimen 
and the clinical outcome following drug exposure, providing 
important insight for optimizing CML therapy.
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Figure S1 Estimated odds ratios of the full logistic regression model of MCyR.
Notes: The outside edges of the open boxes represent the estimated odds ratio at 
the fifth percentile of continuous predictor values; the open circles represent odds 
relative to the reference value of the categorical predictor variable; the outside 
edges of the shaded boxes represent the estimated odds ratio at the 95th percentile 
of continuous covariate values; the horizontal lines represent the 95% confidence 
intervals of estimated effects.
Abbreviations: MCyR, major cytogenetic response; wCavgss, weighted average 
steady-state plasma dasatinib concentration.
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Figure S2 Estimated hazard ratios of the full Cox proportional hazards model of 
pleural effusion.
Notes: The outside edges of the open boxes represent the estimated hazard ratio 
at the fifth percentile of continuous predictor values; the open circles represent 
hazard relative to the reference value of the categorical predictor variable; the 
outside edges of the shaded boxes represent the estimated hazard ratio at the 95th 
percentile of continuous covariate values; the horizontal lines represent the 95% 
confidence intervals of estimated effects.
Abbreviation: Cmin, trough plasma dasatinib concentration.
Table S2 Baseline demographic and laboratory values of 
patients in the population pharmacokinetic analysis
Covariate N Value
Median (range) age, years 981 55 (15–86)
Median (range) weight, kg 961 75 (38–180)
Mean (SD) BMI, kg/m2 905 26.9 (5.4)
Male/female, n (%) 981 484 (49)/497 (51)
Race, n (%) 
 Caucasian 
 Asian 
 Black/African American 
 Other 
 Unknown
981  
816 (83) 
83 (8) 
49 (5) 
30 (3) 
3 (0.3)
Mean (SD) ALT, IU/L 944 26.2 (19.3)
Mean (SD) AST, IU/L 946 27.7 (16.8)
Mean (SD) creatinine clearance, mL/min 926 93.8 (35.4)
Mean (SD) baseline hemoglobin, g/dL 954 11.8 (2.0)
Mean (SD) baseline WBC count, ×103 cells/μL 959 20.6 (30.7)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
BMI, body mass index; SD, standard deviation; WBC, white blood cell.
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